Form 4: Aclaris Therapeutics Director Anand Mehra Reports Stock Transaction

Director Anand Mehra of Aclaris Therapeutics reports the vesting of restricted stock units and subsequent disposition of shares.

Summary

• On June 1, 2024, Anand Mehra, a director of Aclaris Therapeutics, had 4,660 restricted stock units vest.
• These units converted into common stock, which were then disposed of.
• Following the transaction, Mehra directly owns 43,364 shares of Aclaris Therapeutics.
• The filing also includes a Power of Attorney, dated May 28, 2024, authorizing Kevin Balthaser, Matthew Rothman, Mark Ballantyne, David Brinton, and Robin Lee to act on Mehra's behalf for SEC filings related to Aclaris Therapeutics.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing, reflecting neutral sentiment as it reports a transaction without expressing any positive or negative outlook.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders, such as directors and officers, ensuring fair market practices.

Stakeholder Impact

• Shareholders are informed about the stock transactions of a company director, contributing to transparency.
• The filing ensures compliance with SEC regulations, maintaining investor confidence.

Key Dates